Precision BioSciencesNASDAQ: DTIL

Precision BioSciences (DTIL) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $3 per share a year ago.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. “With the clearance of our first clinical trial application (CTA) for our lead program, PBGENE-HBV, we have arrived at the next phase of Precision's jou.

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B Investor Event on Friday, November 15, 2024, from 7:00 a.m. – 8:30 a.m. PST prior to the American Association for the Study of Liver Diseases (AASLD) Meeting. The event will feature Key Opinion Leaders in the field of Hepat.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. Longwood Boston CEO Conference Date: Monday, October 28, 2024 Time: 11:10 AM ET Title: Expanding Platform Potential Format: Panel Guggenheim Inaugural Healthcare Conference Date.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) is an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion which is necessary for diseases where a defective gene is remedied by expression of a new DNA sequence, today announced a poster presentation at the upcoming European Society of Gene & Cell Therapy (ESGCT) Congress being held October 22-25,.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits including viral gene elimination, today announced that the Company will present during a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference taking place October 8, 2024. Presentation Details: Date: October 8, 2024 Time: 11:00AM ET Format: F.

The average of price targets set by Wall Street analysts indicates a potential upside of 277.6% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Precision BioSciences (DTIL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.